Dyadic International (DYAI) Cash from Investing Activities (QoQ) (2018 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Cash from Investing Activities (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 170.46% |
| Dec 31, 2025 | 401.02% |
| Sep 30, 2025 | 109.72% |
| Jun 30, 2025 | -299.46% |
| Mar 31, 2025 | -61.84% |
| Dec 31, 2024 | 10,647.51% |
| Sep 30, 2024 | 99.52% |
| Jun 30, 2024 | -277.56% |
| Mar 31, 2024 | -2,017.51% |
| Dec 31, 2023 | -99.03% |
| Sep 30, 2023 | 214.63% |
| Jun 30, 2023 | -59.49% |
| Mar 31, 2023 | 347.83% |
| Dec 31, 2022 | 147.17% |
| Sep 30, 2022 | -13.27% |
| Jun 30, 2022 | -122.03% |
| Mar 31, 2022 | -111.57% |
| Dec 31, 2021 | 12.34% |
| Sep 30, 2021 | -99.93% |
| Jun 30, 2021 | 199.94% |